Cancer Cell-Based HIT Antibody Detection Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting heparin-induced thrombocytopenia antibodies (HIT Abs) are either inaccurate, require fresh blood platelets, or are costly and complex, making early and reliable diagnosis challenging, especially in urgent cases like COVID-19 patients.
Innovation Solution
A method using cancer cells or their membranes to bind platelet factor 4 (PF4) antigens, allowing for specific detection of HIT Abs through electrostatic interactions, which distinguishes between HIT and non-HIT Abs, employing a standard ELISA protocol with a labeled secondary anti-human antibody.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ELISA or functional assays are used to detect HIT Abs, then detection sensitivity can be achieved, but the methods require fresh blood platelets which are only available in special laboratories and have high costs
Solution Approach 1:
The patent extracts the essential function of platelets (binding HIT Abs through PF4) and implements it using cancer cells expressing PF4. This removes the requirement for fresh blood platelets while maintaining the diagnostic capability, allowing the test to be performed in routine laboratories without specialized sample collection infrastructure.
Solution Approach 2:
The patent creates a substitute system using cancer cells that copy the key functional property of platelets - the ability to bind HIT Abs via PF4 expression. This artificial system replicates the diagnostic function without requiring the original biological material (fresh platelets), enabling widespread laboratory implementation.
2Reliability
If traditional platelet-based assays are used, then HIT Abs detection is possible, but the methods are complex and require specialized laboratory infrastructure
Solution Approach 1:
The patent removes the complex infrastructure requirements by extracting only the essential diagnostic function (PF4-HIT Abs interaction) and implementing it in a simplified system using cancer cells that can be cultured and stored, eliminating the need for specialized platelet collection and handling facilities.
Solution Approach 2:
The patent changes the biological substrate from fresh platelets to cultured cancer cells, fundamentally altering the sample preparation parameters. This allows the use of standard cell culture techniques and storage methods available in routine laboratories, dramatically reducing infrastructure complexity while maintaining diagnostic reliability.
3Productivity
If standard ELISA is used for HIT Abs detection, then cost-effectiveness and batch processing are achieved, but the method cannot distinguish between HIT Abs and non-HIT Abs leading to false positives
Solution Approach 1:
The patent applies local quality by making the ELISA surface heterogeneous - coating it with cancer cells that express PF4. This localized PF4 expression on the cell surface creates specific binding sites that selectively capture HIT Abs, while the cellular context provides additional specificity features that prevent non-specific binding of non-HIT Abs, solving the false positive problem while maintaining batch processing capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a highly specific, cost-effective, and rapid method for detecting HIT Abs, capable of differentiating between HIT and non-HIT Abs, reducing the risk of false positives/negatives and enabling large batch testing without the need for fresh blood platelets.
Implementation Method 1
The key of the invention is the finding that cancer cells or fragments thereof, such as membranes of cancer cells are highly negative-charged surfaces that allow binding of the positively charged platelet factor 4 (PF4) antigens via electrostatic interaction.
Implementation Method 2
adhering a secondary anti-human antibody, which is preferably labeled; and which is capable of binding to the bound HIT Abs on said cells on the solid phase support
Data Source
Figure 1A~2C
Figure 3A~3B
Figure 4A~4B
AI summary
The invention relates to method for the detection of heparin-induced thrombocytopenia antibodies (HIT Abs) in a biological sample comprising the steps of i) providing a solid phase support, wherein said solid support is coated with cells or cell membranes on the surface, ii) binding of platelet factor 4 (PF4) to said cells on the solid phase support, iii) incubating the solid phase support of step ii) with a biological sample, iv) binding of HIT Abs which are present in said biological sample to PF4 on said cells on the solid phase support, v) adhering a secondary anti-human antibody, which is preferably labeled; and which is capable of binding to the bound HIT Abs on said cells on the solid phase support, and vi) detecting the presence of the secondary anti-human antibody, wherein the detection of said secondary anti-human antibody is a positive indicator for the presence HIT Abs in the biological sample, characterized in that said cells or cell membranes on the solid phase support are cancer cells or membranes from cancer cells. The invention further relates to use of said method for diagnosing heparin-induced thrombocytopenia in a subject, and a kit for diagnosing heparin-induced thrombocytopenia in a subject.